Basilar Artery Occlusion Clinical Trial
— pc-ASTEROfficial title:
Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial
NCT number | NCT05320263 |
Other study ID # | 2018_0105 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | November 19, 2022 |
Est. completion date | July 2027 |
Acute ischemic stroke (AIS) patients with basilar artery occlusion (BAO) present a devastating, life-threatening prognosis. Urgent recanalization with endovascular mechanical thrombectomy is routinely performed in patients with BAO although the level of evidence is lower than that in anterior circulation occlusions (randomization in this population versus medical treatment alone having been impossible in recent studies). Recently, a large retrospective study supports the interest of thrombectomy in this population . Speed and grade of the recanalisation have a major impact on clinical outcome. Favorable outcome at 90 days is strongly associated with the successful recanalization status at the end of the endovascular procedure (OR=4.57, 95%CI=1.24-16.87, P=0.023). First pass effect has been shown to be a strong marker of efficacy of endovascular procedure with significant correlation with clinical outcome. Thrombectomy with Stent retrievers dramatically changed the prognosis of anterior circulation large vessel occlusion strokes and currently used in BAO patients (posterior circulation). Contact aspiration (CA) is currently used in anterior large vessel occlusions (COMPASS trial, Lancet 2019), with similar rates of recanalization and favorable outcomes (Boulanger M, 2019), as well as in BAO patients . However, the benefit of CA compared to SR for the treatment of BAO remains under debate with the superiority of first line CA compared to SR or no difference. Available data are based on retrospective studies with no data from RCT. In this context, a randomized controlled trial is needed to assess the benefit of CA versus SR.
Status | Recruiting |
Enrollment | 480 |
Est. completion date | July 2027 |
Est. primary completion date | July 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Age = 18 years - AIS with BAO on non-invasive imaging (CT or MRI) - Eligible for thrombectomy : groin puncture undergone within 24 hours of first symptoms or of last time the patient was seen normal - Being covered by a national health insurance - Informed consent obtained from the patients/his proxy or following an emergency procedure Exclusion Criteria: - Known or suspected pre-existing (chronic) large vessel stenosis / occlusion in the symptomatic territory (basilar artery) - Severe contrast medium allergy or absolute contraindication to use of iodinated products - Clinical history, past imaging or clinical judgment suggesting intracranial stenosis of the basilar artery - Pregnancy (urine or serum beta HCG test for women of child-bearing potential) - Person deprived of liberty - Patient benefiting from a legal protection (guardianship or curatorship) |
Country | Name | City | State |
---|---|---|---|
France | Chu Bordeaux | Bordeaux | |
France | CHU Caen | Caen | |
France | CHU Limoges | Limoges | |
France | CHU Montpellier | Montpellier | |
France | Chru Nancy | Nancy | |
France | Chu Nantes | Nantes | |
France | APHP - Pitié Salpêtrière | Paris | |
France | Fondation Adolphe de Rothschild | Paris | |
France | CHU de Reims | Reims | |
France | CHU Rennes | Rennes | |
France | Hôpital FOCH | Suresnes | |
France | CHU de Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of first pass effect (FPE) defined by complete reperfusion after first device pass | The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy | 24 hours | |
Secondary | Rate of complete reperfusion after first-line thrombectomy strategy and at the end of endovascular procedure | mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular.
mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion |
24 hours | |
Secondary | Rate of successful reperfusion (mTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure | mTICI score is evaluated between 0 to 3. Rate of patients with mTICI score equals to 2b/2c/3 after first-line thrombectomy strategy and at the end of endovascular procedure will be evaluated. | 24 hours | |
Secondary | Rate of near to complete reperfusion (mTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure | 24 hours | ||
Secondary | Rate of Arterial Occlusive Lesion (AOL) recanalization score III after first-line thrombectomy strategy and at the end of endovascular procedure | AOL recanalization score is evaluated between 0 to 3 :
0 indicates no recanalization of the primary occlusive lesion 3 indicates complete recanalization of the primary occlusive lesion with any distal flow |
24 hours | |
Secondary | Groin puncture time to successful reperfusion time (evaluated in minutes) | 360 minutes | ||
Secondary | Modified Rankin Score (mRS) at 3 and 12 months | mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death. | 12 months | |
Secondary | Rate of good functional outcome at 90-day and at one year defined by a mRS 0-3 or equal to pre-stroke mRS (Modified Rankin Score) | 12 months | ||
Secondary | Quality of life at 90 days and 12 months assessed by EuroQol 5D-5L scale | EuroQol 5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. | 12 months | |
Secondary | All cause of mortality at 90-day and 12 months | 12 months | ||
Secondary | 24-hours change in NIHSS (National Institutes of Health Stroke Scale) from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission. | NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity | 24 hours | |
Secondary | Subgroups analysis : Age (=70 vs. >70 years) | 24 hours | ||
Secondary | Subgroups analysis :Baseline NIHSS=10 vs NIHSS<10 (18) | 24 hours | ||
Secondary | Subgroups analysis : Volume of infarct area assessed by pc-ASPECTS (=7 vs. >7) | A pc-ASPECTS score of 10 indicates absence of visible ischemic changes in the posterior circulation, and pc-ASPECTS score of 0 indicates ischemic changes in the midbrain, pons, and bilateral thalami, posterior circulation territories, and cerebellar hemispheres | 24 hours | |
Secondary | Subgroups analysis : Time from admission of patient in hospital to randomization (= 300 vs. > 300 minutes) | 360 minutes | ||
Secondary | Subgroups analysis: Baseline site of thrombi on vascular imaging (Top of the basilar artery vs other adjudicated by the core lab) | 24 hours | ||
Secondary | Subgroups analysis: Prior use of IV alteplase (yes vs. no) | 24 hours | ||
Secondary | Subgroups analysis : Collateral status (good versus poor, as adjudicated by the core lab on initial angiogram) with a 0-3 scale | Collateral circulation is estimated by angiography with a 0-3 scale. The collateral status will be categorized as poor collaterals (scores 0-1) and good collaterals (scores 2-3) | 24 hours | |
Secondary | Incidence of any intracerebral hemorrhage (ICH), parenchymal hematoma (PH), symptomatic ICH on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24±12h after thrombectomy (according to ECASS3 classification) | ECASS III (European Cooperative Acute Stroke Study) classification :
Hemorrhage infarction type 1 (HI1) Hemorrhage infarction type 2 (HI2) Parenchymal hematoma type 1 (PH1) Parenchymal hematoma type 2 (PH2) |
24 hours | |
Secondary | Incidence of procedure-related complications defined as arterial perforation, arterial dissection, embolization in a new territory (ENT) and subarachnoid haemorrhage | hours | ||
Secondary | Cost-effectiveness analysis at 12 months | Incremental cost-effectiveness ratio (ICER, cost per quality-adjusted life year [QALY]), of Contact Aspiration (CA) first-line thrombectomy compared to standard first-line SR thrombectomy in treatment of AIS due to BAO, from a collective perspective and with a 12-months' time horizon. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01717755 -
Basilar Artery International Cooperation Study
|
N/A | |
Recruiting |
NCT06101667 -
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
|
N/A | |
Recruiting |
NCT05615038 -
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
|
N/A | |
Recruiting |
NCT05105633 -
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04177615 -
Randomized Assessment of Rapid Endovascular Treatment in Basilar Artery Occlusion Stroke in 115 Hospital
|
N/A | |
Recruiting |
NCT05827042 -
Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion
|
Phase 3 | |
Recruiting |
NCT05701956 -
Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion
|
Phase 3 | |
Active, not recruiting |
NCT02737189 -
Basilar Artery Occlusion Chinese Endovascular Trial
|
N/A | |
Not yet recruiting |
NCT05580822 -
Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion
|
Phase 2 | |
Completed |
NCT04751708 -
Endovascular Treatment for Acute Basilar Artery Occlusion
|
N/A | |
Recruiting |
NCT05512910 -
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)
|
Phase 4 | |
Recruiting |
NCT05402878 -
OUTCOME AND SAFETY OF RECANALIZATION TREATMENTS IN ISCHEMIC STROKE DUE TO ACUTE BASILAR ARTERY OCCLUSION
|
||
Recruiting |
NCT05631847 -
Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke
|
N/A |